Herceptin®: increasing survival in metastatic breast cancer

This publication has 24 references indexed in Scilit:

• What is HER2?
  European Journal of Oncology Nursing, 2000
• Multinational Study of the Efficacy and Safety of Humanized Anti-HER2 Monoclonal Antibody in Women Who Have HER2-Overexpressing Metastatic Breast Cancer That Has Progressed After Chemotherapy for Metastatic Disease
  Journal of Clinical Oncology, 1999
• Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women.
  Journal of Clinical Oncology, 1998
• Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer.
  Journal of Clinical Oncology, 1996
• Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
  Breast Cancer Research and Treatment, 1992
• Humanization of an anti-p185HER2 antibody for human cancer therapy.
  Proceedings of the National Academy of Sciences, 1992
• Growth Factors and Cancer
  Science, 1991
• Efficacy of Antibodies to Epidermal Growth Factor Receptor Against KB Carcinoma In Vitro and in Nude Mice
  JNCI Journal of the National Cancer Institute, 1988
• erb B-2 Is a Potent Oncogene When Overexpressed in NIH/3T3 Cells
  Science, 1987
• The Product of the Human c- erb B-2 Gene: a 185-Kilodalton Glycoprotein with Tyrosine Kinase Activity
  Science, 1986